Humacyte
HUMA· Manufacturing· Fiscal year ends in December
Laura E. Niklason is the CEO of Humacyte and was paid $905.4K in FY2024 (Dec).
Executives3
See all- 1Laura E. NiklasonPresident and Chief Executive OfficerFY2024
- 2Dale A. SanderChief Financial Officer, Chief Corporate Development Officer and TreasurerFY2024
- 3Shamik J. ParikhChief Medical OfficerNot disclosed
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allHumacyte paid its 3 named executives $2.3M in total in FY2024 (Dec). CEO Laura E. Niklason was paid $905.4K of that.
| Name | ||
|---|---|---|
| Laura E. NiklasonPresident and Chief Executive Officer | ||
| Dale A. SanderChief Financial Officer, Chief Corporate Development Officer and Treasurer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers17
See allThe FY2025 (Dec) proxy of Humacyte names 17 peer companies for pay. Among Humacyte and these peers, CEO pay was 7th highest of 12 and total shareholder return was 9th highest of 12.
7th highest of 12in Humacyte and its pay peers, FY2025 (Dec) by CEO pay:
9th highest of 12in Humacyte and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board4
See all- Brady W. DouganDirector · 4 yr on the boardNot independent—Paid as an executive
- Emery N. BrownDirector · 4 yr on the boardIndependentNominating and Governance—Paid as an executive
- Max WallaceDirector · 4 yr on the boardIndependentCompensation, Nominating and Governance (Chair)—Paid as an executive
- Michael T. ConstantinoDirector · 4 yr on the boardIndependentAudit (Chair), Compensation—Paid as an executive
The board of the latest proxy (FY2025).
Activity
- Left the market25
Filings6
See all| Proxy statement | DEF 14A | Apr 28, 2026 | FY2025 |
| Annual report | 10-K | Mar 27, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 29, 2025 | FY2024 |
| Annual report | 10-K | Mar 31, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 29, 2024 | FY2023 |
| Annual report | 10-K | Mar 28, 2024 | FY2023 |